RY 139.89 0.8943% TD 76.9 1.2242% SHOP 86.16 -18.5248% CNR 172.89 0.5818% ENB 51.15 1.1269% CP 112.14 0.5199% BMO 127.56 0.9816% TRI 229.43 0.1528% CNQ 105.96 1.0105% BN 60.44 0.683% ATD 75.02 0.4015% CSU 3820.47 1.7341% BNS 65.64 1.4685% CM 66.73 1.3364% SU 53.67 0.4304% TRP 52.0 1.069% NGT 57.07 0.3693% WCN 227.19 0.0528% MFC 33.6 0.9919% BCE 46.16 0.5445%
Last update at 2024-05-08T19:51:00Z
| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Income before tax | -24.42054M | -6.96554M | -5.32131M | -3.97127M | -3.69863M |
| Minority interest | - | - | - | - | - |
| Net income | -24.53854M | -7.00676M | -5.33543M | -3.96560M | -3.70833M |
| Selling general administrative | 7.83M | 2.29M | 2.48M | 2.00M | 1.47M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | 0.44M | 0.27M | 0.23M | 0.06M | - |
| Ebit | -24.17648M | -6.86595M | -5.22091M | -3.96967M | -3.68892M |
| Ebitda | -23.73648M | -6.59875M | -4.99568M | -3.90820M | -3.62439M |
| Depreciation and amortization | 0.44M | 0.27M | 0.23M | 0.06M | 0.06M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -24.17648M | -6.86595M | -5.22091M | -3.96967M | -3.68892M |
| Other operating expenses | 24.75M | 6.94M | 5.26M | 4.01M | 3.71M |
| Interest expense | 0.12M | 0.06M | 0.09M | 0.00727M | 0.00971M |
| Tax provision | - | - | 0.00000M | - | - |
| Interest income | 0.33M | 0.02M | 0.02M | 0.04M | 0.00781M |
| Net interest income | 0.46M | 0.01M | -0.04743M | 0.03M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.12M | 0.04M | 0.01M | -0.00567M | 0.00971M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 24.75M | 6.94M | 5.26M | 4.01M | 3.71M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | -0.24406M | -0.09958M | -0.10040M | -0.00160M | -0.00971M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -24.42054M | -6.96554M | -5.32131M | -3.97127M | - |
| Net income applicable to common shares | -24.42054M | -6.96554M | -5.32131M | -3.97127M | -3.69863M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Total assets | 52.48M | 29.82M | 5.73M | 5.57M | 3.61M |
| Intangible assets | 0.52M | 0.72M | 0.92M | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.17M | - | - | - | 0.10M |
| Total liab | 4.88M | 1.75M | 1.58M | 0.69M | 0.34M |
| Total stockholder equity | 47.61M | 28.07M | 4.14M | 4.88M | 3.26M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.99M | 0.98M | 0.32M | 0.21M | 0.16M |
| Common stock | 110.99M | 74.01M | 44.64M | 41.31M | 33.89M |
| Capital stock | 110.99M | 74.01M | 44.64M | 41.31M | - |
| Retained earnings | -79.16949M | -54.74895M | -47.78341M | -42.46210M | -38.49083M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 0.22M | 0.21M | - | - | - |
| Cash | 3.78M | 27.87M | 3.95M | 1.80M | 1.74M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4.74M | 1.48M | 0.88M | 0.69M | 0.34M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -3.50007M | -27.48084M | -3.24680M | -1.79714M | -1.73935M |
| Short term debt | 0.14M | 0.12M | 0.03M | 0.00000M | 0.00000M |
| Short long term debt | - | - | 0.03M | - | - |
| Short long term debt total | 0.28M | 0.39M | 0.70M | - | - |
| Other stockholder equity | 15.79M | 8.81M | 7.29M | 6.04M | 7.86M |
| Property plant equipment | 0.65M | 0.56M | 0.20M | 0.25M | 0.29M |
| Total current assets | 51.09M | 28.33M | 4.61M | 5.32M | 3.32M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 47.09M | 27.35M | 3.23M | 4.88M | - |
| Short term investments | 46.00M | - | 0.00000M | 2.01M | 1.00M |
| Net receivables | 1.15M | 0.45M | 0.51M | 0.74M | 0.47M |
| Long term debt | - | 0.00000M | 0.70M | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 3.61M | 0.38M | 0.53M | 0.47M | 0.18M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.22M | 0.60M | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.39M | 1.49M | 1.12M | 0.25M | 0.29M |
| Capital lease obligations | 0.28M | 0.39M | - | - | - |
| Long term debt total | 0.14M | 0.28M | 0.70M | 0.00000M | 0.00000M |
| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Investments | -46.34131M | -0.22878M | 0.99M | -1.02002M | - |
| Change to liabilities | 3.31M | 0.46M | 0.22M | 0.32M | - |
| Total cashflows from investing activities | -46.34131M | -0.22878M | 0.99M | -1.02002M | -0.11066M |
| Net borrowings | -0.16856M | -0.02800M | 0.87M | 4.56M | - |
| Total cash from financing activities | 36.66M | 31.00M | 5.10M | 5.27M | 3.14M |
| Change to operating activities | -0.16381M | 0.14M | 0.63M | -0.67660M | - |
| Net income | -24.42054M | -6.96554M | -5.32131M | -3.97127M | -3.69863M |
| Change in cash | -24.09814M | 23.92M | 2.15M | 0.06M | -0.88817M |
| Begin period cash flow | 27.87M | 3.95M | 1.80M | 1.74M | 2.63M |
| End period cash flow | 3.78M | 27.87M | 3.95M | 1.80M | 1.74M |
| Total cash from operating activities | -14.42140M | -6.84374M | -3.93920M | -4.19239M | -3.91601M |
| Issuance of capital stock | 20.28M | 21.13M | 3.54M | 4.56M | - |
| Depreciation | 0.44M | 0.27M | 0.23M | 0.06M | 0.06M |
| Other cashflows from investing activities | -46.01231M | -0.21155M | 2.00M | -0.99602M | 0.00437M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.19504M | -0.08980M | 0.01M | 0.11M | - |
| Sale purchase of stock | 36.51M | 29.90M | 3.56M | 4.73M | 2.81M |
| Other cashflows from financing activities | 16.55M | 9.90M | 1.65M | 0.71M | 3.14M |
| Change to netincome | 6.61M | -0.66296M | 0.29M | -0.03767M | - |
| Capital expenditures | 0.33M | 0.02M | 1.01M | 0.02M | 0.12M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 2.95M | 0.52M | 0.86M | -0.24493M | -0.14169M |
| Stock based compensation | 7.45M | 0.22M | 0.68M | 0.88M | 0.53M |
| Other non cash items | -0.83857M | -0.88136M | -0.38888M | -0.91343M | -0.66630M |
| Free cash flow | -14.75040M | -6.86097M | -4.94483M | -4.21639M | -4.03104M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| SVA Sernova Corp |
-0.03 7.50% | 0.37 | - | - | - | 7.95 | -4.4095 | |
| FRX Fennec Pharmaceuticals Inc |
0.15 1.20% | 12.65 | - | 33.33 | 29.10 | 84.57 | 30.47 | -23.3985 |
| EPRX Eupraxia Pharmaceuticals Inc |
-0.03 0.75% | 3.96 | - | - | - | 8.40 | -3.9163 | |
| TH Theratechnologies Inc. |
-0.04 2.35% | 1.66 | - | 55.25 | 1.64 | 19.46 | 2.23 | -11.7353 |
| ONC Oncolytics Biotech Inc |
0.01 0.62% | 1.62 | - | - | - | 4.00 | -2.3144 |
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells;a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform; and research collaboration with AstraZeneca PLC to evaluate novel potential therapeutic cell applications. The company was incorporated in 1998 and is headquartered in London, Canada.
The Stiller Centre, London, ON, Canada, N6G 4X8
| Name | Title | Year Born |
|---|---|---|
| Mr. Frank A. Holler MBA | Exec. Chairman | 1957 |
| Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. | Pres, CEO & Director | NA |
| Mr. David Swetlow C.A, C.A., CPA | Chief Financial Officer | NA |
| Mr. Douglas Maret | Chief Science Officer | NA |
| Mr. Christopher Barnes | VP of Investor Relations | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
CA 
AU
UK
US
NZ
Please wait processing your request...